ライフサイエンスコーパス: oestrogen receptor

1 ifen metabolites that most strongly bind the oestrogen receptor.

2 d a small effect on the binding affinity for oestrogen receptor.

3 r4.1 and glutamate transporter 1 via genomic oestrogen receptors.

4 ptors (beta-AR) and independently of classic oestrogen receptors.

5 the glucocorticoid and progesterone, but not oestrogen, receptors.

6 fied a subset of VMHvl neurons marked by the oestrogen receptor 1 (Esr1), and investigated their role

7 Oestrogen receptor 1-expressing (Esr1(+)) neurons in the

8 ut a very different pattern was observed for oestrogen receptor 2 (ER2).

9 have tumours with variable concentrations of oestrogen-receptors, a surrogate for other biomarkers as

10 rogen receptor corepressor REA (repressor of oestrogen receptor activity), can repress androgen recep

11 through regulation of androgen receptor and oestrogen receptor activity.

12 In addition to its activity as an oestrogen receptor agonist/antagonist, tamoxifen also mo

13 st cancer cells 17beta-oestradiol (E2)-bound oestrogen receptor alpha (ER-alpha) causes a global incr

14 liferation, decreased apoptosis and elevated oestrogen receptor alpha (ERalpha) expression.

15 functions as a coactivator of the endogenous oestrogen receptor alpha (ERalpha) in breast cancer cell

16 Oestrogen receptor alpha (ERalpha) is a nuclear receptor

17 The oestrogen receptor alpha (ERalpha) is expressed in prost

18 Previous studies suggest oestrogen receptor alpha (ERalpha) is involved in oestro

19 Oestrogen, often via oestrogen receptor alpha (ERalpha) signalling, regulates

20 crine therapies target the activation of the oestrogen receptor alpha (ERalpha) via distinct mechanis

21 says and supershift assays using recombinant oestrogen receptor alpha and anti-oestrogen receptor ant

22 r clinical studies have linked response with oestrogen receptor alpha expression and other biomarkers

23 nor FGFR2 allele associates most strongly in oestrogen receptor alpha positive (ERalpha) breast tumou

24 light the essential elements of the membrane oestrogen receptor alpha, noting where conserved aspects

25 ly, CB sparks the constitutive activation of oestrogen receptors alpha (ERalpha) in AI-resistant cell

26 Oestrogen receptor-alpha (ER) is the defining and drivin

27 ime, we present a genome-wide global view of oestrogen receptor-alpha (ERalpha) binding events in the

28 or (PR) expression is used as a biomarker of oestrogen receptor-alpha (ERalpha) function and breast c

29 ified a direct interaction between Hippo and oestrogen receptor-alpha (ERalpha) signalling.

30 se range of transcription factors, including oestrogen receptor-alpha (ERalpha).

31 opoietic stem cells expressed high levels of oestrogen receptor-alpha (ERalpha).

32 ation-associated breast cancer originates in oestrogen receptor-alpha-negative (ER(-)) progenitors in

33 s with negligible affinities for the nuclear oestrogen receptor also strongly inhibited high K(+)-ind

34 and FOXM1, and is inversely correlated with oestrogen receptor and directly correlated with FOXM1 in

35 e show that the ability of SRC-1 to bind the oestrogen receptor and enhance its transcriptional activ

36 goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast c

37 age, radiotherapy intent, nodal status, and oestrogen receptor and HER-2 status.

38 st-line treatment), hormone receptor status (oestrogen receptor and progesterone receptor positive vs

39 ks, and stratified by previous chemotherapy, oestrogen-receptor and progesterone-receptor status, and

40 KBP12.6-null mice treated with tamoxifen, an oestrogen receptor antagonist, develop cardiac hypertrop

41 4.1 expression reduced in the presence of an oestrogen receptor antagonist, Fulvestrant 182,780 sugge

42 s inhibitor, an RNA synthesis inhibitor, and oestrogen receptor antagonists did not affect the inhibi

43 ecombinant oestrogen receptor alpha and anti-oestrogen receptor antibody localized the sequence motif

44 The discovery of oestrogen receptor beta (ERbeta/ESR2) was a landmark dis

45 eport the three-dimensional structure of the oestrogen receptor beta isoform (ERbeta) ligand-binding

46 In addition, oestrogen receptor beta ligand treatment caused an incre

47 Oestrogen receptor beta ligand treatment of experimental

48 ings show a direct neuroprotective effect of oestrogen receptor beta ligand treatment on oligodendroc

49 resent study we investigated the capacity of oestrogen receptor beta ligand treatment to affect callo

50 inated axons with intact nodes of Ranvier in oestrogen receptor beta ligand-treated mice.

51 -oestradiol, which induces proliferation via oestrogen receptor-beta (ER-beta), the catecholoestradio

52 ning residues -658 to -1 modified to abolish oestrogen receptor binding at this site, confirmed the f

53 actions enriched for both enhancer marks and oestrogen receptor-binding sites.

54 known that male reproductive tissues express oestrogen receptors, but the role of oestrogen in male r

55 pective of age, menopausal status, or tumour oestrogen-receptor concentration (hazard ratio [HR] for

56 patients' age, menopausal status, and tumour oestrogen-receptor concentration.

57 Older women tend to have higher tumour oestrogen-receptor concentrations and are more likely to

58 e them to age, menopausal status, and tumour oestrogen-receptor concentrations.

59 has 54% homology at the protein level to the oestrogen receptor corepressor REA (repressor of oestrog

60 se mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy.

61 We investigated whether the selective oestrogen receptor degrader fulvestrant could improve pr

62 PI3K, AKT, and HER2, and a new generation of oestrogen-receptor degraders.

63 nin to the ligand-binding domain of a mutant oestrogen receptor (DeltaNbeta-cateninER).

64 ormonal agents, the aromatase inhibitors and oestrogen-receptor downregulators, which have no oestrog

65 o the hormone-binding domain of the modified oestrogen receptor (ER(TAM)) can be regulated by provisi

66 Oestrogen receptor (ER) alpha is a well established prog

67 Crosstalk between the oestrogen receptor (ER) and ERBB2/HER-2 pathways has lon

68 INCX upregulation by E2 was blunted by an oestrogen receptor (ER) antagonist (fulvestrant, 1 mum),

69 ICI 182 780 is a pure steroidal oestrogen receptor (ER) antagonist that blocks oestrogen

70 Oestrogen receptor (ER) is a good prognostic marker for

71 stry are more likely to have young-onset and oestrogen receptor (ER) negative breast cancer for reaso

72 In oestrogen receptor (ER) positive breast epithelial cells

73 Oestrogen receptor (ER) positive tumour-derived cell lin

74 ith different survival patterns according to oestrogen receptor (ER) status.

75 ession of the progesterone receptor (PR) and oestrogen receptor (ER) was associated with subtype-spec

76 ated the effects of BAG-1 on function of the oestrogen receptor (ER), a key growth control molecule a

77 tor-1 (SRC-1), a coregulatory protein of the oestrogen receptor (ER), has previously been shown to ha

78 ancer subtypes in 690 Irish women with known oestrogen receptor (ER), progesterone receptor (PR), and

79 1, was significantly associated with risk of oestrogen receptor (ER)-negative breast cancer (odds rat

80 significant associations (P<5 x 10(-8)) with oestrogen receptor (ER)-negative breast cancer and BRCA1

81 scent staining of tumour sections from human oestrogen receptor (ER)-negative breast cancer patients

82 PHGDH protein levels are elevated in 70% of oestrogen receptor (ER)-negative breast cancers.

83 nt of axillary nodes, 276 (33%) patients had oestrogen receptor (ER)-negative disease, and 191 (27%)

84 rs of breast cancer survival involving 1,804 oestrogen receptor (ER)-negative patients treated with c

85 More aggressive and therapy-resistant oestrogen receptor (ER)-positive breast cancers remain a

86 For women with oestrogen receptor (ER)-positive early breast cancer, tr

87 UNX1 expression did not influence outcome of oestrogen receptor (ER)-positive or HER2-positive diseas

88 investigate the role of the top prioritized oestrogen receptor (ER)-regulated lncRNA, DSCAM-AS1.

89 ted by a specific amino acid sequence of the oestrogen receptor (ER).

90 se biological effects through binding to the oestrogen receptor (ER).

91 activity of nuclear receptors including the oestrogen receptor (ER).

92 -inducible nuclear transcription factor, the oestrogen receptor (ER).

93 mines tamoxifen sensitivity by regulation of oestrogen receptor (ER)alpha.

94 as no effect for breast cancers negative for oestrogen receptor (ER; hazard ratio 1.22 [0.89-1.67]; p

95 isting of 60 genes for patients positive for oestrogen receptors (ER) and 16 genes for ER-negative pa

96 sodilatory effect by binding to its specific oestrogen receptors (ER) in target cells, resulting in i

97 The interaction between oestrogen receptors (ER) in the lung and epidermal growt

98 Some oestrogen-receptor (ER) positive breast cancers express

99 expression profiling studies have shown that oestrogen-receptor (ER)-positive and ER-negative breast

100 Three patients with oestrogen-receptor (ER)-positive, human epidermal growth

101 culating tumour cells in women with advanced oestrogen-receptor (ER)-positive/human epidermal growth

102 ith hormone-receptor-positive breast cancer (oestrogen receptor [ER] positive, progesterone receptor

103 simultaneously increased Ca(2+) currents via oestrogen receptor ERalpha.

104 5 nm) but not the beta- (DPN, 5 nm) subtype oestrogen receptor (ERalpha/ERbeta) upregulated I(Ca,L)

105 use pancreatic beta-cells from wild-type and oestrogen receptor ERbeta-/- mice, we found that exposur

106 (beta-ARs) and independently of the classic oestrogen receptors (ERs).

107 er samples to assess the correlation between oestrogen receptor (ESR1) and ERBB2 mRNA and clinical st

108 Expression of oestrogen receptor (ESR1) determines whether a breast ca

109 ment of oestrodial metabolizing genes or the oestrogen receptors (Esr1 and 2) in tumour multiplicity.

110 the adult virgin gland is restricted to the oestrogen receptor-expressing luminal cell lineage.

111 Our data also demonstrate that the oestrogen receptor-expressing, milk and basal cell subpo

112 ncer overall, and by tumour histology and by oestrogen receptor expression.

113 Induction of the Myc-oestrogen receptor fusion protein (MycER) by 4-OH-tamoxi

114 s carrying EBV encoding a conditional EBNA3C-oestrogen receptor-fusion revealed that this epigenetic

115 dentify recurrent rearrangements between the oestrogen receptor gene ESR1 and its neighbour CCDC170,

116 ntly shown to activate the G protein-coupled oestrogen receptor (GPER) in vascular cells.

117 target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the de

118 The oestrogen receptor is a member of the nuclear receptor f

119 benzothiophene derivative that binds to the oestrogen receptor, is a selective oestrogen receptor mo

120 Oestrogens and oestrogen receptor ligands are promising treatments to p

121 forms an alternative mechanism of activating oestrogen receptor-mediated transcription.

122 al research defined the concept of selective oestrogen receptor modulation in the 1980s.

123 Tamoxifen is a selective oestrogen receptor modulator widely used for the treatme

124 ds to the oestrogen receptor, is a selective oestrogen receptor modulator, producing oestrogen-agonis

125 We assessed the effectiveness of selective oestrogen receptor modulators (SERMs) on breast cancer i

126 e prevention trials comparing four selective oestrogen receptor modulators (SERMs; tamoxifen, raloxif

127 s (log P ~4-7), comprising several selective oestrogen receptor modulators and a modified testosteron

128 iological effects of oestrogen and selective oestrogen receptor modulators of potential cardiovascula

129 rapy (aromatase inhibitors only vs selective oestrogen receptor modulators only vs both therapies), a

130 ment of chemical cousins, known as selective oestrogen receptor modulators.

131 ds heralded the development of the selective oestrogen-receptor modulators (SERM).

132 Two selective oestrogen-receptor modulators--tamoxifen and raloxifene-

133 as an additional subgroup, characterised as oestrogen receptor negative and androgen receptor positi

134 ssociated with bone relapse in patients with oestrogen-receptor negative breast cancer.

135 estrogen-receptor positive) and MDA-MB-231, (oestrogen-receptor negative) were made resistant to doce

136 east cancer, especially if the recurrence is oestrogen-receptor negative.

137 =0.05), but no effect was noted for invasive oestrogen receptor-negative breast cancer (HR 1.05 [95%

138 tingham-HES; n=1650), Nottingham early stage oestrogen receptor-negative breast cancer adjuvant chemo

139 In patients with oestrogen receptor-negative breast cancer with high SPAG

140 oxic chemotherapy sensitivity, especially in oestrogen receptor-negative breast cancer.

141 The association is stronger for oestrogen receptor-negative disease (OR 0.34, 95% CI 0.2

142 oestrogen receptor-positive disease than for oestrogen receptor-negative disease (p<0.01 for both com

143 oestrogen receptor-positive disease than for oestrogen receptor-negative disease and for lobular than

144 who did not receive chemotherapy (Nottingham-oestrogen receptor-negative-ACT cohort: HR 0.37, 95% CI

145 cer adjuvant chemotherapy cohort (Nottingham-oestrogen receptor-negative-ACT; n=697), the Nottingham

146 3 (0.69-1.00, p=0.05) when 122 patients with oestrogen-receptor-negative disease were excluded.

147 significantly more effective for women with oestrogen-receptor-negative ILRR (pinteraction=0.046), b

148 sing a chimaeric p53 fusion protein with the oestrogen receptor (p53ER) to supply p53 (p53 is induced

149 For older women with oestrogen-receptor-poor tumours who did not receive tamo

150 nal candidate, rs4442975, is associated with oestrogen receptor positive (ER+) disease with an odds r

151 esponse to endocrine therapy and survival in oestrogen receptor positive breast cancer is a significa

152 sponders and non-responders in patients with oestrogen receptor positive breast cancer.

153 resected unilateral breast cancer (that was oestrogen-receptor positive or of unknown status), who w

154 Breast cancer cells, MCF-7 (oestrogen-receptor positive) and MDA-MB-231, (oestrogen-

155 mutations in breast cancer, specifically in oestrogen receptor-positive (ER(+)) tumours.

156 tion of phenotypes in concordance with human oestrogen receptor-positive (ER+) breast cancer samples,

157 lationship between mutations and response of oestrogen receptor-positive (ER+) breast cancer to aroma

158 ions leading to the more aggressive forms of oestrogen receptor-positive (ER+) breast cancers is of c

159 patients were enrolled on the basis of their oestrogen receptor-positive and HER2-negative biomarker

160 ression-free survival in women with advanced oestrogen receptor-positive and HER2-negative breast can

161 2 study, postmenopausal women with advanced oestrogen receptor-positive and HER2-negative breast can

162 atest reduction in risk was seen in invasive oestrogen receptor-positive breast cancer (HR 0.66 [95%

163 al evidence of growth-inhibitory activity in oestrogen receptor-positive breast cancer cells and syne

164 Poor-prognosis oestrogen receptor-positive breast cancer is characteris

165 n three genomic regions focally amplified in oestrogen receptor-positive breast cancer, 8p11-12, 11q1

166 issue, aberrant production of which promotes oestrogen receptor-positive breast cancer.

167 ive disease (OR 0.34, 95% CI 0.21-0.54) than oestrogen receptor-positive disease (OR 0.63, 95% CI 0.4

168 enous ovarian hormones are more relevant for oestrogen receptor-positive disease than for oestrogen r

169 trends by age at menopause were stronger for oestrogen receptor-positive disease than for oestrogen r

170 cells and also, although at lower levels, in oestrogen receptor-positive luminal cells.

171 dose (1.7 micromol kg(-1), 1 T), but not in oestrogen receptor-positive MCF-7 tumours.

172 gible patients with histologically confirmed oestrogen receptor-positive or progesterone receptor-pos

173 nhances oestrogen-dependent transcription in oestrogen receptor-positive tumour cells and promotes th

174 e increased risk appears largely confined to oestrogen receptor-positive tumour risk.

175 ant can improve progression-free survival in oestrogen receptor-positive, endocrine-resistant breast

176 menopausal women aged 18 years or older with oestrogen receptor-positive, HER2-negative breast cancer

177 st-line treatment of patients with advanced, oestrogen receptor-positive, HER2-negative breast cancer

178 stmenopausal women with early stage hormone (oestrogen) receptor-positive invasive breast cancer were

179 ence single normal and tumour nuclei from an oestrogen-receptor-positive (ER(+)) breast cancer and a

180 o oestrogen-deprivation therapy is common in oestrogen-receptor-positive (ER+) breast cancer.

181 These include a high-risk, oestrogen-receptor-positive 11q13/14 cis-acting subgroup

182 has been made in identifying the drivers of oestrogen-receptor-positive breast cancer and the mechan

183 Distinct phenotypes in oestrogen-receptor-positive breast cancer are associated

184 e bank from all postmenopausal patients with oestrogen-receptor-positive breast cancer from whom the

185 Oestrogen-receptor-positive breast cancer is the most co

186 for postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer showed that ch

187 is prognostic for women with node-negative, oestrogen-receptor-positive breast cancer treated with t

188 correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic a

189 therapy for late recurrence in patients with oestrogen-receptor-positive breast cancer would be clini

190 e replacement therapy, either overall or for oestrogen-receptor-positive disease.

191 after tamoxifen in postmenopausal women with oestrogen-receptor-positive early breast cancer.

192 Patients with oestrogen-receptor-positive ILRR received adjuvant endoc

193 enopausal patients with unilateral invasive, oestrogen-receptor-positive or oestrogen-receptor-unknow

194 An ESR1 mRNA cutoff value of 500 identified oestrogen-receptor-positive status with an overall accur

195 s showed that tamoxifen benefited women with oestrogen-receptor-positive tumours and negative axillar

196 has been achieved in treatment of women with oestrogen-receptor-positive tumours and negative nodes.

197 patients with early stage breast cancer and oestrogen-receptor-positive tumours.

198 tissue was available from 665 patients with oestrogen-receptor-positive, N0 breast cancer for BCI an

199 h early and late recurrence in patients with oestrogen-receptor-positive, node-negative (N0) disease

200 Because 90% of tumours are oestrogen-receptor-positive, tamoxifen is standard adjuv

201 ch tumour cells do not express the genes for oestrogen receptor, progesterone receptor and HER2 (also

202 cers and to establish if these are linked to oestrogen receptor, progesterone receptor, and human epi

203 ta will be available for how factors such as oestrogen receptor, progesterone receptor, HER2, and ind

204 s focused on women with tumours positive for oestrogen receptor, progesterone receptor, or both.

205 g LINC00160 expressions and interaction with oestrogen receptor signalling.

206 orted by systemic therapy appropriate to the oestrogen receptor status (ER) of the tumour, local radi

207 involved axillary lymph nodes, tumour stage, oestrogen receptor status, type and timing of systemic t

208 GeneChip reliably and reproducibly establish oestrogen-receptor status and ERBB2 status, respectively

209 nd might be used at the same time to confirm oestrogen-receptor status and ERBB2 status.

210 es of disease-free survival according to the oestrogen-receptor status of the primary tumour were not

211 known prognostic factors (age, nodal status, oestrogen-receptor status, grade, and tumour size).

212 axillary lymph nodes, clinical tumour stage, oestrogen-receptor status, type and timing of systemic t

213 after control for tumour grade, tumour size, oestrogen-receptor status, vascular invasion, and treatm

214 zoledronic acid on DFS were not affected by oestrogen-receptor status.

215 )-inducible telomerase reverse transcriptase-oestrogen receptor (TERT-ER) under transcriptional contr

216 idues in a conserved helix (helix 12) of the oestrogen receptor that are required for its ligand-indu

217 TRIM24 binds chromatin and oestrogen receptor to activate oestrogen-dependent genes

218 ral invasive, oestrogen-receptor-positive or oestrogen-receptor-unknown breast cancer who were diseas

219 tibody localized the sequence motif to which oestrogen receptor was binding to residues -225 to -212

220 Fusions of the ligand-binding domain of the oestrogen receptor with the DBD of RFX4 occur in some hu